Request for Information on “Update on Selected Topics in Asthma Management 2020: A Report From the National Asthma Education and Prevention Program Coordinating Committee (NAEPPCC) Expert Panel Report 4 (EPR-4) Working Group”, 65991-65992 [2019-26017]
Download as PDF
<![CDATA[
jbell on DSKJLSW7X2PROD with NOTICES
Federal Register / Vol. 84, No. 231 / Monday, December 2, 2019 / Notices
Name of Committee: National Cancer
Institute Special Emphasis Panel; SEP–2: NCI
Clinical and Translational R21 and Omnibus
R03.
Date: January 30–31, 2020.
Time: 7:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: Ombretta Salvucci, Ph.D.,
Scientific Review Officer, Special Review
Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W264, Rockville, MD
20850, 240–276–7286, salvucco@
mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; TEP–4:
Cloud-Based Software for the Cancer
Research Data Common.
Date: February 6, 2020.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W246, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Jun Fang, Ph.D., Scientific
Review Officer, Research Technology &
Contract Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
Room 7W246, Rockville, MD 20850, (240)
276–5460, jfang@mail.nih.gov.
Name of Committee: National Cancer
Institute Initial Review Group; Subcommittee
F—Institutional Training and Education.
Date: February 24–25, 2020.
Time: 6:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda Marriott Suites, 6711
Democracy Boulevard, Bethesda, MD 20817.
Contact Person: Adriana Stoica, Ph.D.,
Scientific Review Officer, Resources and
Training Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
7W234, Bethesda, MD 20892–9750, 240–276–
6368, Stoicaa2@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Innovative
Molecular and Cellular Analysis
Technologies.
Date: March 4–5, 2020.
Time: 4:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda North Marriott Hotel &
Conference Center. Montgomery County
Conference Center Facility. 5701 Marinelli
Road. North Bethesda, MD 20852.
Contact Person: Jun Fang, Ph.D., Scientific
Review Officer, Research Technology &
Contract Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
Room 7W246, Rockville, MD 20850, (240)
276–5460, jfang@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Participant
Engagement and Cancer Genome Sequencing
Centers.
VerDate Sep<11>2014
17:10 Nov 29, 2019
Jkt 250001
Date: March 17–18, 2020.
Time: 4:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda North Marriott Hotel &
Conference Center, Montgomery County
Conference Center Facility, 5701 Marinelli
Road, North Bethesda, MD 20852.
Contact Person: Shakeel Ahmad, Ph.D.,
Chief, Research Technology and Contract
Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 7W102,
Rockville, MD 20850, 240–276–6442,
ahmads@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; SEP–5: NCI
Clinical and Translational R21 and Omnibus
R03 Review Meeting.
Date: March 26, 2020.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda North Marriott Hotel &
Conference Center, Montgomery County
Conference Center Facility, 5701 Marinelli
Road, North Bethesda, MD 20852.
Contact Person: Adriana Stoica, Ph.D.,
Scientific Review Officer, Resources and
Training Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
7W234, Bethesda, MD 20892–9750, 240–276–
6368, Stoicaa2@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: November 25, 2019.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–25984 Filed 11–29–19; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Request for Information on ‘‘Update on
Selected Topics in Asthma
Management 2020: A Report From the
National Asthma Education and
Prevention Program Coordinating
Committee (NAEPPCC) Expert Panel
Report 4 (EPR–4) Working Group’’
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Request for Information.
The Expert Panel Working
Group of the NHLBI National Asthma
Education and Prevention Program
Coordinating Committee (NAEPPCC) is
SUMMARY:
PO 00000
Frm 00027
Fmt 4703
Sfmt 4703
65991
soliciting comments and suggestions
from the public on ‘‘Update on Selected
Topics in Asthma Management 2020: A
Report from the Expert Panel Report-4
(EPR–4) Working Group.’’ This Request
for Information (RFI) invites the
scientific community, health
professionals, organizations, patient
communities, and the general public to
provide comments and suggestions,
including particular emphasis on the
feasibility, acceptability, and capacity
for implementation, of the proposed
recommendations and implementation
guidance. Responses to this RFI will be
used to update and revise the report as
necessary.
DATES: The NHLBI NAEPPCC RFI is
open for public comment for a period of
35 days. Comments must be received by
January 6, 2020 to ensure consideration.
After the public comment period has
closed, the comments received will be
considered in a timely manner by the
NHLBI NAEPPCC Expert Panel Working
Group.
ADDRESSES: Submissions may be
submitted electronically to [https://
www.epr4workgroup.org/
Asthma2020Guidelines] or by mail to
[Asthma2020Guidelines@westat.com].
FOR FURTHER INFORMATION CONTACT:
Questions about this request for
information should be directed to Susan
T. Shero, RN, MS, Executive Secretary,
NAEPPCC, National Heart, Lung, and
Blood Institute, National Institutes of
Health, 6701 Rockledge Blvd., Rm.
9182, Bethesda, MD 20892,
Asthma2020Guidelines@westat.com,
301–496–1051.
SUPPLEMENTARY INFORMATION:
The NHLBI NAEPPCC
In August 2015, the National Asthma
Education and Prevention Program
Coordinating Committee (NAEPPCC)
was chartered as a federal advisory
committee in accordance with 424B of
the Public Health Service Act, 42 U.S.C.
285b–7b, as amended. The committee is
governed by the provisions of the
Federal Advisory Committee Act
(FACA), as amended (5 U.S.C App.),
which sets forth standards for the
formation and use of advisory
committees. The NAEPPCC fulfills the
charges of 424B of the Public Health
Service Act, 42 U.S.C. 285b–7b, as
amended:
• Identify all Federal programs that
carry out asthma-related activities.
• Develop, in consultation with
appropriate federal agencies and
professional and voluntary health
organizations, a Federal plan for
responding to asthma.
E:\FR\FM\02DEN1.SGM
02DEN1
65992
Federal Register / Vol. 84, No. 231 / Monday, December 2, 2019 / Notices
jbell on DSKJLSW7X2PROD with NOTICES
The NAEPPCC also fulfills charges,
similar to those above, set forth in the
Children’s Health Act of 2000 (Pub. L.
106–310). In addition, the Children’s
Health Act of 2000 tasks the NHLBI,
through the NAEPPCC, with submitting
recommendations to Congress on ways
to strengthen and improve coordination
of asthma-related activities of the
federal government.
The NAEPPCC consists of
representatives from the major
scientific, professional, governmental,
and voluntary organizations interested
in asthma. The Committee’s primary
mission is to advise the NHLBI on
matters concerning asthma and to
facilitate the exchange of information on
asthma activities among the member
agencies and voluntary health
organizations.
The NHLBI administers and
coordinates the Coordinating
Committee. The Coordinating
Committee meetings are open to the
public and include presentations and
discussion on a variety of topics
concerning asthma, including activities
and projects of the Committee.
NHLBI Asthma Guidelines
NHLBI produced its first asthma
clinical practice guidelines in 1991 and
an update was issued in 2007,
Guidelines for the Diagnosis and
Management of Asthma (EPR–3). In
2011, the National Asthma Education
and Prevention Program concluded
another update was needed and an
Advisory Council of the NHLBI
determined in 2012 that a needs
assessment should be conducted prior
to engaging in any guideline activity. In
2014, NHLBI Council convened an
Asthma Expert Panel Working Group to
conduct a needs assessment. The
Working Group recommended that an
update should be made to the 2007
clinical practice guidelines; identified
five priority topics for immediate
systematic review and update
(subsequently changed to six priority
topics); and recommended that the
NHLBI maintain the NAEPP structure,
coordinate the systematic reviews, and
update the report. After public
comments on the draft needs assessment
report were received and reviewed, the
Working Group recommended adding a
sixth priority topic to the report.
The six priority topic areas identified
by the Working Group are: (1)
Adjustable medication dosing in
recurrent wheezing and asthma
(‘‘intermittent therapy’’), (2) long acting
anti-muscarinic agents in asthma
management as add-on to inhaled
corticosteroids, (3) bronchial
thermoplasty in adult severe asthma, (4)
VerDate Sep<11>2014
17:10 Nov 29, 2019
Jkt 250001
fractional exhaled nitric oxide (FeNO)
in diagnosis, medication selection, and
monitoring treatment response, (5)
remediation of indoor allergens (house
dust mites/pets), and (6) the role of
immunotherapy in the treatment of
asthma.
The Working Group also
recommended that several emerging
topic areas be acknowledged and
monitored, but did not yet merit
systematic review.
NAEPPCC Expert Panel Report 4 (EPR–
4) Working Group
The NAEPPCC Expert Panel Working
Group 4 (EPR–4) was established in
2018 to update selected topics in the
2007 Guidelines for the Diagnosis and
Management of Asthma, Expert Panel
Report 3 (EPR–3). The Expert Panel
Working Group members used findings
from the following NHLBI-supported
systematic reviews to develop updates
to the 2007 guidelines.
• Role of Immunotherapy in the
Treatment of Asthma
• Intermittent Inhaled Corticosteroids
and Long-Acting Muscarinic Antagonist
for Asthma
• Effectiveness of Indoor Allergen
Reduction in Management of Asthma
• Effectiveness and Safety of
Bronchial Thermoplasty in Management
of Asthma
• The Clinical Utility of Fractional
Exhaled Nitric Oxide (FeNO) in Asthma
Management
The Expert Panel Working Group
members include asthma content
experts, specialists and primary care
clinicians, health policy experts,
implementation and dissemination
experts and individuals with experience
using the GRADE (Grading of
Recommendations Assessment,
Development and Evaluation) approach.
A methodologist provided technical
support to the Working Group.
This RFI should not be construed as
a solicitation for applications or
proposals, or as an obligation in any
way on the part of the United States
Federal government. The Federal
government will not pay for the
preparation of any information
submitted or for the government’s use.
Additionally, the government cannot
guarantee the confidentiality of the
information provided.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Advancing
Translational Sciences; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center for
Advancing Translational Sciences Special
Emphasis Panel—SBIR.
Date: December 18, 2019.
Time: 1:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, One
Democracy Plaza, 6701 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Jing Chen, Ph.D., Scientific
Review Officer, Office of Scientific Review,
National Center for Advancing Translational
Sciences (NCATS), National Institutes of
Health, 6701 Democracy Blvd., Democracy 1,
Room 1080, Bethesda, MD 20892–4874,
chenjing@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.350, B—Cooperative
Agreements; 93.859, Biomedical Research
and Research Training, National Institutes of
Health, HHS)
Dated: November 25, 2019.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–25985 Filed 11–29–19; 8:45 am]
BILLING CODE 4140–01–P
Dated: October 30, 2019.
James P. Kiley,
Director, Division of Lung Diseases, NHLBI.
[FR Doc. 2019–26017 Filed 11–29–19; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00028
Fmt 4703
Sfmt 9990
E:\FR\FM\02DEN1.SGM
02DEN1
]]>Agencies
[Federal Register Volume 84, Number 231 (Monday, December 2, 2019)]
[Notices]
[Pages 65991-65992]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-26017]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Request for Information on ``Update on Selected Topics in Asthma
Management 2020: A Report From the National Asthma Education and
Prevention Program Coordinating Committee (NAEPPCC) Expert Panel Report
4 (EPR-4) Working Group''
AGENCY: National Institutes of Health, HHS.
ACTION: Request for Information.
-----------------------------------------------------------------------
SUMMARY: The Expert Panel Working Group of the NHLBI National Asthma
Education and Prevention Program Coordinating Committee (NAEPPCC) is
soliciting comments and suggestions from the public on ``Update on
Selected Topics in Asthma Management 2020: A Report from the Expert
Panel Report-4 (EPR-4) Working Group.'' This Request for Information
(RFI) invites the scientific community, health professionals,
organizations, patient communities, and the general public to provide
comments and suggestions, including particular emphasis on the
feasibility, acceptability, and capacity for implementation, of the
proposed recommendations and implementation guidance. Responses to this
RFI will be used to update and revise the report as necessary.
DATES: The NHLBI NAEPPCC RFI is open for public comment for a period of
35 days. Comments must be received by January 6, 2020 to ensure
consideration. After the public comment period has closed, the comments
received will be considered in a timely manner by the NHLBI NAEPPCC
Expert Panel Working Group.
ADDRESSES: Submissions may be submitted electronically to [https://www.epr4workgroup.org/Asthma2020Guidelines] or by mail to
[[email protected]].
FOR FURTHER INFORMATION CONTACT: Questions about this request for
information should be directed to Susan T. Shero, RN, MS, Executive
Secretary, NAEPPCC, National Heart, Lung, and Blood Institute, National
Institutes of Health, 6701 Rockledge Blvd., Rm. 9182, Bethesda, MD
20892, [email protected], 301-496-1051.
SUPPLEMENTARY INFORMATION:
The NHLBI NAEPPCC
In August 2015, the National Asthma Education and Prevention
Program Coordinating Committee (NAEPPCC) was chartered as a federal
advisory committee in accordance with 424B of the Public Health Service
Act, 42 U.S.C. 285b-7b, as amended. The committee is governed by the
provisions of the Federal Advisory Committee Act (FACA), as amended (5
U.S.C App.), which sets forth standards for the formation and use of
advisory committees. The NAEPPCC fulfills the charges of 424B of the
Public Health Service Act, 42 U.S.C. 285b-7b, as amended:
Identify all Federal programs that carry out asthma-
related activities.
Develop, in consultation with appropriate federal agencies
and professional and voluntary health organizations, a Federal plan for
responding to asthma.
[[Page 65992]]
The NAEPPCC also fulfills charges, similar to those above, set
forth in the Children's Health Act of 2000 (Pub. L. 106-310). In
addition, the Children's Health Act of 2000 tasks the NHLBI, through
the NAEPPCC, with submitting recommendations to Congress on ways to
strengthen and improve coordination of asthma-related activities of the
federal government.
The NAEPPCC consists of representatives from the major scientific,
professional, governmental, and voluntary organizations interested in
asthma. The Committee's primary mission is to advise the NHLBI on
matters concerning asthma and to facilitate the exchange of information
on asthma activities among the member agencies and voluntary health
organizations.
The NHLBI administers and coordinates the Coordinating Committee.
The Coordinating Committee meetings are open to the public and include
presentations and discussion on a variety of topics concerning asthma,
including activities and projects of the Committee.
NHLBI Asthma Guidelines
NHLBI produced its first asthma clinical practice guidelines in
1991 and an update was issued in 2007, Guidelines for the Diagnosis and
Management of Asthma (EPR-3). In 2011, the National Asthma Education
and Prevention Program concluded another update was needed and an
Advisory Council of the NHLBI determined in 2012 that a needs
assessment should be conducted prior to engaging in any guideline
activity. In 2014, NHLBI Council convened an Asthma Expert Panel
Working Group to conduct a needs assessment. The Working Group
recommended that an update should be made to the 2007 clinical practice
guidelines; identified five priority topics for immediate systematic
review and update (subsequently changed to six priority topics); and
recommended that the NHLBI maintain the NAEPP structure, coordinate the
systematic reviews, and update the report. After public comments on the
draft needs assessment report were received and reviewed, the Working
Group recommended adding a sixth priority topic to the report.
The six priority topic areas identified by the Working Group are:
(1) Adjustable medication dosing in recurrent wheezing and asthma
(``intermittent therapy''), (2) long acting anti-muscarinic agents in
asthma management as add-on to inhaled corticosteroids, (3) bronchial
thermoplasty in adult severe asthma, (4) fractional exhaled nitric
oxide (FeNO) in diagnosis, medication selection, and monitoring
treatment response, (5) remediation of indoor allergens (house dust
mites/pets), and (6) the role of immunotherapy in the treatment of
asthma.
The Working Group also recommended that several emerging topic
areas be acknowledged and monitored, but did not yet merit systematic
review.
NAEPPCC Expert Panel Report 4 (EPR-4) Working Group
The NAEPPCC Expert Panel Working Group 4 (EPR-4) was established in
2018 to update selected topics in the 2007 Guidelines for the Diagnosis
and Management of Asthma, Expert Panel Report 3 (EPR-3). The Expert
Panel Working Group members used findings from the following NHLBI-
supported systematic reviews to develop updates to the 2007 guidelines.
Role of Immunotherapy in the Treatment of Asthma
Intermittent Inhaled Corticosteroids and Long-Acting
Muscarinic Antagonist for Asthma
Effectiveness of Indoor Allergen Reduction in Management
of Asthma
Effectiveness and Safety of Bronchial Thermoplasty in
Management of Asthma
The Clinical Utility of Fractional Exhaled Nitric Oxide
(FeNO) in Asthma Management
The Expert Panel Working Group members include asthma content
experts, specialists and primary care clinicians, health policy
experts, implementation and dissemination experts and individuals with
experience using the GRADE (Grading of Recommendations Assessment,
Development and Evaluation) approach. A methodologist provided
technical support to the Working Group.
This RFI should not be construed as a solicitation for applications
or proposals, or as an obligation in any way on the part of the United
States Federal government. The Federal government will not pay for the
preparation of any information submitted or for the government's use.
Additionally, the government cannot guarantee the confidentiality of
the information provided.
Dated: October 30, 2019.
James P. Kiley,
Director, Division of Lung Diseases, NHLBI.
[FR Doc. 2019-26017 Filed 11-29-19; 8:45 am]
BILLING CODE 4140-01-P
